Loading company…
Riskpilot
← Back to search
Sign in
Get full access
IMMUNOQUEST THERAPEUTICS AS
AS
Active
Org 931892266
Gaustadalléen 21, 0349 Oslo
Research and experimental development on natural sciences and engineering · NACE 7210
Est. 2023
0 employees
Watchlist
Share
Overview
Financials
People & ownership
Related companies
Revenue 2024
NOK 0
EBITDA margin
—
Equity ratio
-164.9%
Financial strength
Net profit 2024
NOK -752K
-25050233% vs 2023
EBITDA — year on year
NOK millions
0M
-0M
-1M
-1M
-1M
0M
2023
-1M
-100%
2024
Key figures
Annual report 2024
Revenue
NOK 0
—
EBITDA
NOK -712K
—
Net profit
NOK -752K
-25050233%
Total assets
NOK 438K
+1359%
Equity
NOK -721K
-2505%
Employees
0
—
Company information
Legal name
IMMUNOQUEST THERAPEUTICS AS
Org number
931892266
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
15. august 2023
Share capital
NOK 43 019
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Forskning og utvikling av kreftbehandling.
Contact
Address
Gaustadalléen 21, 0349 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Research and experimental development on natural sciences and engineering
Companies in Oslo
All Norway companies
Revenue
NOK millions
0M
0M
1M
1M
1M
0M
2023
0M
2024
EBITDA
NOK millions
0M
0M
1M
1M
1M
0M
2023
-1M
2024
Income statement
NOK thousands
Item
2023
2024
Revenue
0
0
Staff expenses
−0
−604
EBITDA
0
−712
Depreciation & amort.
−0
−6
EBIT
0
−718
Net financials
0
−33
Profit before tax
0
−752
Tax
−0
−0
Net profit
0
−752
Balance sheet
NOK thousands
Item
2023
2024
Total assets
30
438
Equity
30
−721
Long-term debt
0
1 034
Short-term debt
0
125
Total debt
0
1 159
Financial ratios
5-year trend
EBITDA margin
-71248100.0%
This company
15.8%
Market median
-450937442% vs market
2023
2024
Equity ratio
-164.9%
This company
38.2%
Market median
-532% vs market
2023
2024
Return on equity
-75150400.0%
This company
18.4%
Market median
-408426187% vs market
2023
2024
Net profit margin
-75150400.0%
This company
8.1%
Market median
-927782816% vs market
2023
2024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
2023
2024
Debt / equity
1.61×
This company
0.62×
Market median
-160% vs market
2023
2024
Annual reports & filings
Annual report 2024
Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
View
PDF
Management
Actively employed in the business
Name
Role
Member since
Current (1)
KE
Knut Erik Skullerud
Deputy Member
Deputy Member
2026
Board of directors
Non-executive oversight
Name
Role
Member since
Current (6)
OK
Ole Kristian Hjelstuen
Chairman
2023
HS
Håvard Selby Ebbestad
Chairman
2026
MH
Morten Hugo Egeberg
Board of Directors
2024
VG
Vidar Gordon Flote
Board of Directors
2026
KG
Kari Grønås
Board of Directors
2024
AP
Anders Pablo Kapstad
Board of Directors
2024
Shareholders
As of last annual report
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
No registered parent or subsidiaries
Board network connections
Board members of IMMUNOQUEST THERAPEUTICS AS also hold positions in
0
other companies.
Person
Role here
Other companies
Knut Erik Skullerud
Deputy Member
0 companies
Ole Kristian Hjelstuen
Chairman
0 companies
Håvard Selby Ebbestad
Chairman
0 companies
Morten Hugo Egeberg
Board of Directors
0 companies
Vidar Gordon Flote
Board of Directors
0 companies
Kari Grønås
Board of Directors
0 companies
Anders Pablo Kapstad
Board of Directors
0 companies